About Nura Bio
Nura Bio is a company based in San Francisco (United States) founded in 2018 by Marc Freeman and Steve McKnight.. Nura Bio has raised $141 million across 2 funding rounds from investors including The Column Group, Samsara BioCapital and Sanofi Ventures. Nura Bio offers products and services including Neuroprotective Therapies. Nura Bio operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Abbisko Therapeutics, NewAmsterdam Pharma and Healx, among others.
- Headquarter San Francisco, United States
- Founders Marc Freeman, Steve McKnight
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nura Bio ™ Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$141 M (USD)
in 2 rounds
-
Latest Funding Round
$68 M (USD), Series A
Sep 17, 2024
-
Investors
The Column Group
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nura Bio
Nura Bio offers a comprehensive portfolio of products and services, including Neuroprotective Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets pathways for axon degeneration in neurological diseases.
Unlock access to complete
Funding Insights of Nura Bio
Nura Bio has successfully raised a total of $141M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $68 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $68.0M
-
First Round
First Round
(29 Jul 2020)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Series A - Nura Bio | Valuation | TCG | |
| Jul, 2020 | Amount | Series A - Nura Bio | Valuation | TCG |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nura Bio
Nura Bio has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include The Column Group, Samsara BioCapital and Sanofi Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nura Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nura Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nura Bio Comparisons
Competitors of Nura Bio
Nura Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Abbisko Therapeutics, NewAmsterdam Pharma and Healx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for solid tumours and blood cancers
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for rare diseases is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nura Bio
Frequently Asked Questions about Nura Bio
When was Nura Bio founded?
Nura Bio was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Nura Bio located?
Nura Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Nura Bio?
Alpna Seth is the current CEO of Nura Bio.
Is Nura Bio a funded company?
Nura Bio is a funded company, having raised a total of $141M across 2 funding rounds to date. The company's 1st funding round was a Series A of $73M, raised on Jul 29, 2020.
What does Nura Bio do?
NUraBio provides a solution for the diagnosis of a neurological disorder and neuroprotective medicines. The company targets the axonal degeneration and neuroimmune regulation for treating neurological disorders. It also argeting neuron-intrinsic mechanisms and the neuron-glia axis. The lead candidate of the company is small molecule-based SARM1 which is an axon-intrinsic metabolic sensor and regulator with putative immune function. The company also offers tools like x-ray crystallography, cryo-EM, and biophysical platforms for drug discovery, along with genetic screening and biomarker platforms for the identification of translatable biomarkers.
Who are the top competitors of Nura Bio?
Nura Bio's top competitors include Nuvalent, Enliven Therapeutics and Healx.
What products or services does Nura Bio offer?
Nura Bio offers Neuroprotective Therapies.
Who are Nura Bio's investors?
Nura Bio has 4 investors. Key investors include The Column Group, Samsara BioCapital, Sanofi Ventures, and Euclidean Capital.